IOVA
Companies
NASDAQ
Iovance Biotherapeutics, Inc.
Health Care
$2.02
-$5.36 (-72.43%)
Price Chart
Overview
About IOVA
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.
Market Cap
$2.2B
Volume
58.8M
Avg. Volume
32.3M
P/E Ratio
-2.3292682
Dividend Yield
0.00%
Employees
518.0
Company Information
Risk & Correlation Analysis
Market Correlation
1.24
Moderate Correlation
Volatility
High (0.77)
Relative to market
Macro Factor Sensitivities
Interest Rates
Medium Sensitivity
Inflation
Low Sensitivity
GDP Growth
Medium Sensitivity
Liquidity
Low Sensitivity
Commodity Prices
Low Sensitivity
Credit Quality
High Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, IOVA shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Key Statistics
Market Cap$2.2B
Volume58.8M
P/E Ratio-2.33
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
May 9, 2025Pricing info last updated June 17, 2025 (after market close)Other info last updated April 2, 2025